Shares of Oculis Holding AG (NASDAQ:OCS - Get Free Report) traded up 3.8% on Tuesday . The company traded as high as $15.17 and last traded at $15.17. 5,473 shares were traded during mid-day trading, a decline of 85% from the average session volume of 36,819 shares. The stock had previously closed at $14.62.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of Oculis in a research report on Monday, November 11th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $29.20.
Check Out Our Latest Analysis on Oculis
Oculis Stock Up 3.6 %
The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01. The business has a fifty day moving average of $14.35 and a two-hundred day moving average of $12.71.
Oculis (NASDAQ:OCS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. The firm had revenue of $0.27 million during the quarter, compared to analyst estimates of $0.28 million. As a group, equities research analysts expect that Oculis Holding AG will post -2.09 EPS for the current year.
About Oculis
(
Get Free Report)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
